Company Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas.
Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
| Country | Canada |
| Founded | 2003 |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 272 |
| CEO | Kenneth H. Galbraith C.A. |
Contact Details
Address: Suite 800 - 114 East 4th Avenue Vancouver, A1 V5T 1G4 British Columbia, Canada | |
| Phone | (604) 678-1388 |
| Website | zymeworks.com |
Stock Details
| Ticker Symbol | ZYME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403752 |
| CUSIP Number | 98985W102 |
| ISIN Number | US98985Y1082 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Kenneth H. Galbraith C.A. | Chief Executive Officer and Chairman of the Board |
| Dr. Paul Moore Ph.D. | Chief Scientific Officer |
| Mark Hollywood | Executive Vice President and Head of Technical and Manufacturing Operations |
| Daniel Dex J.D., Ph.D. | Senior Vice President, Corporate Secretary and General Counsel |
| Diana Papove | Senior Manager of Corporate Communications |
| Dr. Lindsey Foulkes B.Sc., Ph.D. | Vice President of Corporate Development |
| Laura O'Connor | Vice President of Human Resources and DEI |
| Dr. Jeffrey Smith M.D. | Executive Vice President and Chief Medical Officer |
| Dr. Josemund Menezes MBBS | Managing Director of Early-Stage Development for Asia Pacific |
| John Fann Ph.D. | Senior Vice President of Process Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 6, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2022 | 15-12G | Securities registration termination |
| Oct 21, 2022 | 8-K | Current Report |
| Oct 19, 2022 | 8-K | Current Report |
| Oct 18, 2022 | 8-K | Current Report |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Oct 13, 2022 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |